GSK 256066 Trifluoroacetate |
カタログ番号GC36187 |
GSK 256066 トリフルオロアセテートは選択的で高親和性のホスホジエステラーゼ 4 (PDE) 阻害剤であり、PDE4B の IC50 は 3.2 pM です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1415560-64-3
Sample solution is provided at 25 µL, 10mM.
GSK 256066 Trifluoroacetate is a selective and high-affinity phosphodiesterase 4 (PDE) inhibitor, with an IC50 of 3.2 pM for PDE4B; developed for the treatment of chronic obstructive pulmonary disease[1]. IC50: 3.2 pM (PDE4B)[1]
GSK 256066 Trifluoroacetate is an exceptionally high-affinity inhibitor of PDE4 designed for inhaled administration[1]. GSK 256066 Trifluoroacetate is highly selective for PDE4, with >380,000-fold versus PDE1/2/3/5/6 and >2500-fold against PDE7, and inhibits PDE4 isoforms A-D with equal affinity[1].GSK 256066 Trifluoroacetate inhibits tumor necrosis factor α production by lipopolysaccharide (LPS)-stimulated human peripheral blood monocytes with IC50 of 0.01 nM[1].
GSK 256066 Trifluoroacetate (0.3-100 μg/kg; intratracheally) inhibits the eosinophil number increased in the bronchoalveolar lavage (BAL) in a dose-dependent fashion, in lipopolysaccharide (LPS)- and ovalbumin (OVA)-induced acute pulmonary inflammation rat models.[2].GSK 256066 Trifluoroacetate inhibits LPS-induced pulmonary neutrophilia, and no emetic episodes are observed in ferrets[2]. Animal Model: Male Brown Norway rats(180-200 g)[2]
[1]. Tralau-Stewart CJ, et al. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther, 2011, 337(1), 145-154. [2]. Nials AT, et al. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther, 2011, 337(1), 137-144.
Average Rating: 5
(Based on Reviews and 27 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *